Drugs that contain Encorafenib

1. Drug name - BRAFTOVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8946250 ARRAY BIOPHARMA INC 3,4-diarylpyrazoles as protein kinase inhibitors
Jul, 2029

(6 years from now)

US8541575 ARRAY BIOPHARMA INC 3,4-diarylpyrazoles as protein kinase inhibitors
Feb, 2030

(7 years from now)

US9593099 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US8501758 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Mar, 2031

(8 years from now)

CN102105459A ARRAY BIOPHARMA INC 3,4-Diarylpyrazoles As Protein Kinase Inhibitors
Jul, 2029

(6 years from now)

CN102105459B ARRAY BIOPHARMA INC 3,4-Diarylpyrazoles As Protein Kinase Inhibitors
Jul, 2029

(6 years from now)

CN102725283B ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

CN103896921A ARRAY BIOPHARMA INC Compound And Composition As A Protein Kinase Inhibitor
Aug, 2030

(7 years from now)

CN103896921B ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

CN102725283A ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

IN303554B ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

IN201202469P1 ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

EP2324008B1 ARRAY BIOPHARMA INC 3,4-Diarylpyrazoles As Protein Kinase Inhibitors
Jul, 2029

(6 years from now)

EP2324008A1 ARRAY BIOPHARMA INC 3,4-Diarylpyrazoles As Protein Kinase Inhibitors
Jul, 2029

(6 years from now)

EP2727918A1 ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

EP2470526A1 ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

EP2470526B1 ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

EP2727918B1 ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9850230 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors Aug, 2030

(7 years from now)

US9850229 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors Aug, 2030

(7 years from now)

US9593100 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors Aug, 2030

(7 years from now)

US10005761 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors Aug, 2030

(7 years from now)

US9314464 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors Jul, 2031

(8 years from now)

US10258622 ARRAY BIOPHARMA INC Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate Nov, 2032

(10 years from now)

US9387208 ARRAY BIOPHARMA INC Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate Nov, 2032

(10 years from now)

US9763941 ARRAY BIOPHARMA INC Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate Nov, 2032

(10 years from now)

US9474754 ARRAY BIOPHARMA INC Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor Aug, 2033

(10 years from now)

Treatment: Treatment of melanoma with a braf mutation; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test; Indicated in combination with binimetinib for the treatment of melanoma with a braf mutation; Treatment of melanoma; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test; Treatment of melanoma mediated by a b-raf protein kinase; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test; Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; Treatment of melanoma

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
50MG CAPSULE;ORAL Discontinued
75MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.